交易 Eagle Pharm - EGRX CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|
Eagle Pharm Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
总收入 | 171.546 | 187.802 | 195.892 | 213.312 | 236.707 |
收入 | 171.546 | 187.802 | 195.892 | 213.312 | 236.707 |
收入成本,共计 | 42.18 | 45.465 | 60.897 | 61.916 | 57.186 |
毛利 | 129.366 | 142.337 | 134.995 | 151.396 | 179.521 |
总营业费用 | 168.777 | 154.848 | 174.077 | 176.696 | 162.717 |
销售/一般/行政费用,总计 | 75.322 | 78.598 | 76.37 | 60.509 | 71.416 |
研究与开发 | 51.275 | 30.785 | 36.81 | 44.419 | 32.607 |
异常费用(收入) | 0 | 0 | 10.615 | 8.885 | |
营业收入 | 2.769 | 32.954 | 21.815 | 36.616 | 73.99 |
利息收入(费用),非经营净值 | -7.275 | -2.015 | -0.517 | -2.578 | -1.045 |
其他,净值 | -0.042 | -8.262 | 0.7 | ||
税前净收入 | -4.548 | 22.677 | 21.998 | 34.038 | 72.945 |
税后净收入 | -8.627 | 11.989 | 14.313 | 31.903 | 55.343 |
未计算非常项目前的净收益 | -8.627 | 11.989 | 14.313 | 31.903 | 55.343 |
净收入 | -8.627 | 11.989 | 14.313 | 31.903 | 51.943 |
Total Adjustments to Net Income | |||||
普通股股东可获收益 (不含非经常性项目) | -8.627 | 11.989 | 14.313 | 31.903 | 55.343 |
普通股股东可获收益 (含非經常性項目) | -8.627 | 11.989 | 14.313 | 31.903 | 51.943 |
摊薄净收入 | -8.627 | 11.989 | 14.313 | 31.903 | 51.943 |
摊薄后加权平均股 | 13.0511 | 13.7714 | 14.1387 | 15.2787 | 15.9082 |
扣除特别项目的每股摊薄盈利 | -0.66102 | 0.87057 | 1.01233 | 2.08808 | 3.4789 |
每股正常摊薄盈利 | -0.66102 | 0.87057 | 1.01233 | 2.73926 | 3.90264 |
Other Operating Expenses, Total | 0 | 0 | -0.763 | -7.377 | |
非常规项目总计 | -3.4 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
总收入 | 115.874 | 42.32 | 39.853 | 48.124 | 41.249 |
收入 | 115.874 | 42.32 | 39.853 | 48.124 | 41.249 |
收入成本,共计 | 27.755 | 12.309 | 8.259 | 10.757 | 10.855 |
毛利 | 88.119 | 30.011 | 31.594 | 37.367 | 30.394 |
总营业费用 | 56.045 | 36.421 | 50.03 | 37.304 | 45.022 |
销售/一般/行政费用,总计 | 22.182 | 20.325 | 18.482 | 16.636 | 19.879 |
研究与开发 | 6.108 | 3.787 | 23.289 | 9.911 | 14.288 |
营业收入 | 59.829 | 5.899 | -10.177 | 10.82 | -3.773 |
利息收入(费用),非经营净值 | -2.712 | -4.53 | -2.499 | -5.459 | 5.213 |
其他,净值 | 0.543 | -0.145 | 0.016 | 0.187 | -0.1 |
税前净收入 | 57.66 | 1.224 | -12.66 | 5.548 | 1.34 |
税后净收入 | 44.058 | -6.196 | -5.622 | 3.612 | -0.421 |
未计算非常项目前的净收益 | 44.058 | -6.196 | -5.622 | 3.612 | -0.421 |
净收入 | 44.058 | -6.196 | -5.622 | 3.612 | -0.421 |
普通股股东可获收益 (不含非经常性项目) | 44.058 | -6.196 | -5.622 | 3.612 | -0.421 |
普通股股东可获收益 (含非經常性項目) | 44.058 | -6.196 | -5.622 | 3.612 | -0.421 |
摊薄净收入 | 44.058 | -6.196 | -5.622 | 3.612 | -0.421 |
摊薄后加权平均股 | 12.9068 | 12.8948 | 13.0773 | 13.2622 | 13.0694 |
扣除特别项目的每股摊薄盈利 | 3.41355 | -0.4805 | -0.42991 | 0.27235 | -0.03221 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | 3.41355 | -0.4805 | -0.42991 | 0.27235 | -0.03221 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
流动资产总额 | 172.606 | 166.065 | 179.449 | 163.844 | 188.697 |
现金和短期投资 | 97.659 | 103.155 | 109.775 | 78.791 | 114.657 |
现金等价物 | 97.659 | 103.155 | 109.775 | 78.791 | 114.657 |
应收账款总额,净额 | 41.149 | 51.117 | 48.004 | 66.486 | 53.821 |
Accounts Receivable - Trade, Net | 41.149 | 51.117 | 48.004 | 66.486 | 53.821 |
Total Inventory | 21.908 | 8.075 | 6.566 | 8.304 | 5.118 |
Prepaid Expenses | 11.89 | 3.718 | 15.104 | 10.263 | 15.101 |
Total Assets | 253.732 | 253.19 | 254.554 | 238.603 | 270.06 |
Property/Plant/Equipment, Total - Net | 1.636 | 2.077 | 5.918 | 2.397 | 6.82 |
Property/Plant/Equipment, Total - Gross | 7.591 | 7.268 | 10.237 | 5.744 | 9.258 |
Accumulated Depreciation, Total | -5.955 | -5.191 | -4.319 | -3.347 | -2.438 |
Goodwill, Net | 39.743 | 39.743 | 39.743 | 39.743 | 39.743 |
Intangibles, Net | 10.671 | 12.917 | 15.583 | 18.103 | 23.322 |
Other Long Term Assets, Total | 29.076 | 32.388 | 13.861 | 14.516 | 11.478 |
Total Current Liabilities | 74.376 | 38.085 | 38.823 | 39.686 | 47.302 |
Accounts Payable | 16.431 | 6.268 | 5.462 | 9.917 | 27.036 |
Accrued Expenses | 32.338 | 23.817 | 28.361 | 23.519 | 15.391 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 77.279 | 67.179 | 75.38 | 77.841 | 90.916 |
Total Long Term Debt | 0 | 25.135 | 33.557 | 38.155 | 42.905 |
Other Liabilities, Total | 2.903 | 3.959 | 3 | 0 | 0.709 |
Total Equity | 176.453 | 186.011 | 179.174 | 160.762 | 179.144 |
Common Stock | 0.017 | 0.017 | 0.017 | 0.017 | 0.016 |
Additional Paid-In Capital | 325.779 | 305.403 | 278.518 | 256.458 | 233.639 |
Retained Earnings (Accumulated Deficit) | 75.862 | 84.489 | 72.5 | 58.187 | 26.284 |
Treasury Stock - Common | -225.111 | -203.898 | -171.861 | -153.9 | -80.795 |
Total Liabilities & Shareholders’ Equity | 253.732 | 253.19 | 254.554 | 238.603 | 270.06 |
Total Common Shares Outstanding | 12.7914 | 13.057 | 13.6302 | 13.914 | 14.8477 |
Current Port. of LT Debt/Capital Leases | 25.607 | 8 | 5 | 6.25 | 4.875 |
Long Term Debt | 0 | 25.135 | 33.557 | 38.155 | 42.905 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Other Equity, Total | -0.094 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 240.166 | 172.606 | 171.694 | 175.504 | 163.986 |
现金和短期投资 | 69.522 | 97.659 | 99.741 | 108.717 | 105.229 |
现金等价物 | 69.522 | 97.659 | 99.741 | 108.717 | 105.229 |
应收账款总额,净额 | 130.858 | 41.149 | 47.081 | 52.659 | 44.868 |
Accounts Receivable - Trade, Net | 130.858 | 41.149 | 45.335 | 52.659 | 44.868 |
Total Inventory | 24.818 | 21.908 | 9.315 | 8.294 | 6.862 |
Prepaid Expenses | 14.968 | 11.89 | 15.557 | 5.834 | 7.027 |
Total Assets | 320.165 | 253.732 | 256.261 | 264.242 | 259.968 |
Property/Plant/Equipment, Total - Net | 1.627 | 1.636 | 1.775 | 1.967 | 2.27 |
Property/Plant/Equipment, Total - Gross | 7.759 | 7.591 | 7.542 | 7.537 | 7.652 |
Accumulated Depreciation, Total | -6.132 | -5.955 | -5.767 | -5.57 | -5.382 |
Goodwill, Net | 39.743 | 39.743 | 39.743 | 39.743 | 39.743 |
Intangibles, Net | 9.94 | 10.671 | 10.799 | 11.505 | 12.211 |
Other Long Term Assets, Total | 28.689 | 29.076 | 32.25 | 35.523 | 41.758 |
Total Current Liabilities | 101.642 | 74.376 | 48.431 | 44.664 | 41.973 |
Accounts Payable | 14.509 | 16.431 | 12.717 | 11.136 | 12.559 |
Accrued Expenses | 63.408 | 32.338 | 27.714 | 25.528 | 21.414 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 23.725 | 25.607 | 8 | 8 | 8 |
Total Liabilities | 104.205 | 77.279 | 70.968 | 69.395 | 68.89 |
Total Long Term Debt | 0 | 0 | 19.489 | 21.371 | 23.253 |
Long Term Debt | 0 | 19.489 | 21.371 | 23.253 | |
Other Liabilities, Total | 2.563 | 2.903 | 3.048 | 3.36 | 3.664 |
Total Equity | 215.96 | 176.453 | 185.293 | 194.847 | 191.078 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.017 | 0.017 | 0.017 | 0.017 | 0.017 |
Additional Paid-In Capital | 328.769 | 325.779 | 320.566 | 316.249 | 312.323 |
Retained Earnings (Accumulated Deficit) | 119.92 | 75.862 | 82.058 | 87.68 | 84.068 |
Treasury Stock - Common | -233.164 | -225.111 | -216.466 | -208.195 | -205.33 |
Total Liabilities & Shareholders’ Equity | 320.165 | 253.732 | 256.261 | 264.242 | 259.968 |
Total Common Shares Outstanding | 12.6971 | 12.7914 | 12.9446 | 13.0971 | 13.1455 |
Other Equity, Total | 0.418 | -0.094 | -0.882 | -0.904 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
净收入/起跑线 | -8.627 | 11.989 | 14.313 | 31.903 | 51.943 |
经营活动产生的现金 | 28.219 | 49.497 | 55.986 | 52.384 | 58.919 |
经营活动产生的现金 | 0.764 | 0.872 | 2.131 | 1.155 | 0.932 |
Amortization | 2.996 | 2.666 | 2.52 | 2.515 | 2.815 |
Deferred Taxes | -3.618 | -1.511 | 0.152 | -2.468 | 17.289 |
非现金物品 | 27.167 | 34.665 | 22.478 | 27.168 | 15.509 |
Cash Taxes Paid | 10.005 | 6.428 | 6.673 | 2.281 | 10.542 |
已付现金利息 | 1.197 | 2.224 | 2.478 | 2.084 | 0.651 |
营运资金的变化 | 9.537 | 0.816 | 14.392 | -7.889 | -29.569 |
投资活动产生的现金 | -5.323 | -18.247 | -0.777 | -0.133 | -5.186 |
资本支出 | -0.323 | -0.747 | -0.777 | -0.133 | -5.186 |
其他投资现金流量项目,总计 | -5 | -17.5 | 0 | 0 | |
融资活动产生的现金 | -28.392 | -37.87 | -24.225 | -88.117 | 8.104 |
融资现金流项目 | -1.577 | -1.525 | -0.524 | -19.877 | -1.192 |
股票的发行(报废),净额 | -18.815 | -31.345 | -17.701 | -64.49 | -39.454 |
现金净变化 | -5.496 | -6.62 | 30.984 | -35.866 | 61.837 |
债务的发行(退还),净额 | -8 | -5 | -6 | -3.75 | 48.75 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 44.058 | -8.627 | -2.431 | 3.191 | -0.421 |
Cash From Operating Activities | -16.611 | 28.219 | 20.138 | 19.071 | 10.478 |
Cash From Operating Activities | 0.177 | 0.764 | 0.575 | 0.378 | 0.19 |
Amortization | 0.731 | 2.996 | 2.118 | 1.412 | 0.706 |
Deferred Taxes | -2.432 | -3.618 | -2.533 | 1.119 | 0.902 |
Non-Cash Items | 6.616 | 27.167 | 17.689 | 10.989 | 1.378 |
Cash Taxes Paid | 0.041 | 10.005 | 6.303 | 4.3 | 0.267 |
Cash Interest Paid | 0.265 | 1.197 | 0.917 | 0.625 | 0.321 |
Changes in Working Capital | -65.761 | 9.537 | 4.72 | 1.982 | 7.723 |
Cash From Investing Activities | -0.168 | -5.323 | -5.274 | -5.269 | -5.384 |
Capital Expenditures | -0.168 | -0.323 | -0.274 | -0.269 | -0.384 |
Other Investing Cash Flow Items, Total | 0 | -5 | -5 | -5 | -5 |
Cash From Financing Activities | -11.358 | -28.392 | -18.278 | -8.24 | -3.02 |
Financing Cash Flow Items | -1.305 | -1.577 | -1.551 | -1.551 | -1.551 |
Issuance (Retirement) of Stock, Net | -8.053 | -18.815 | -10.727 | -2.689 | 0.531 |
Issuance (Retirement) of Debt, Net | -2 | -8 | -6 | -4 | -2 |
Net Change in Cash | -28.137 | -5.496 | -3.414 | 5.562 | 2.074 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 12.5669 | 1635783 | 7863 | 2022-12-31 | LOW |
Tarriff (Scott L) | Individual Investor | 12.3402 | 1606275 | 70900 | 2023-03-01 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 9.4485 | 1229872 | -9907 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 7.3139 | 952026 | -59721 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.8538 | 761974 | -11708 | 2022-12-31 | LOW |
Brandes Investment Partners, L.P. | Investment Advisor | 3.1973 | 416177 | -51680 | 2022-12-31 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 3.073 | 400000 | 150000 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.6858 | 349606 | -6153 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 2.0485 | 266650 | -7629 | 2022-12-31 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.7792 | 231587 | -79633 | 2022-12-31 | MED |
Smith, Graham & Co. Investment Advisors, L.P. | Investment Advisor | 1.7764 | 231222 | -799 | 2022-12-31 | LOW |
Quoniam Asset Management GmbH | Investment Advisor/Hedge Fund | 1.766 | 229871 | -55740 | 2022-12-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5388 | 200305 | 3708 | 2022-12-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 1.2517 | 162931 | 19807 | 2022-12-31 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.231 | 160236 | -2596 | 2022-12-31 | LOW |
LSV Asset Management | Investment Advisor | 1.1633 | 151418 | 126068 | 2022-12-31 | LOW |
Allspring Global Investments, LLC | Investment Advisor/Hedge Fund | 1.1572 | 150628 | 62456 | 2022-12-31 | LOW |
Scout Investments, Inc. | Investment Advisor | 1.0805 | 140642 | -2342 | 2022-12-31 | MED |
AQR Capital Management, LLC | Investment Advisor/Hedge Fund | 1.0396 | 135315 | 39400 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 1.0331 | 134477 | -15478 | 2022-12-31 | MED |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Eagle Pharm Company profile
关于 Eagle Pharm
鹰牌制药公司是一家综合性制药公司。 公司将一个分子从临床前研究到监管部门批准并进入市场,包括开发、制造和商业化。 公司确定了具有挑战性的中枢神经系统疾病或代谢性危重病治疗领域以及肿瘤学领域。 该公司提供三种产品。 Ryanodex,丹曲林钠)(Ryanodex),苯达莫司汀即溶(RTD)500毫升溶液(Belrapzo),以及快速输注苯达莫司汀RTD(Bendeka)。 公司销售Ryanodex和Belrapzo,而梯瓦制药工业有限公司(Teva)销售Bendeka。 (Teva)在日本销售盐酸苯达莫司汀的冻干粉制剂Bendeka。
Industry: | Proprietary & Advanced Pharmaceuticals |
50 Tice Boulevard, Suite 315
WOODCLIFF LAKE
NEW JERSEY 07677
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。